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Abstract
End-stage renal disease (ESRD) presenting in a familial autosomal dominant pattern points to an
underlying monogenic cause. Nail-patella syndrome (NPS) is an autosomal dominant disorder that
may lead to ESRD caused by mutations in the transcription factor LMX1B. Renal-limited forms of
this disease, termed nail-patella-like renal disease (NPLRD), and LMX1B nephropathy have recently
been described. We report a large family, from the North East of England, with seven affected
members with varying phenotypes of renal disease, ranging from ESRD at 28 years of age to micro-
scopic haematuria and proteinuria and relatively preserved renal function. In this family, there
were no extra-renal manifestations to suggest NPS. Genome-wide linkage studies and inheritance
by descent (IBD) suggested disease loci on Chromosome 1 and 9. Whole exome sequencing (WES)
analysis identified a novel sequence variant (p.R249Q) in the LMX1B gene in each of the three
samples submitted, which was confirmed using Sanger sequencing. The variant segregated with
the disease in all affected individuals. In silicomodelling revealed that R249 is putatively located in
close proximity to the DNA phosphoskeleton, supporting a role for this residue in the interaction
between the LMX1B homeodomain and its target DNA. WES and analysis of potential target genes,
including CD2AP, NPHS2, COL4A3, COL4A4 and COL4A5, did not reveal any co-inherited pathogenic
variants. In conclusion, we confirm a novel LMX1B mutation in a large family with an autosomal
dominant pattern of nephropathy. This report confirms that LMX1Bmutations may cause a glomer-
ulopathy without extra-renal manifestations. A molecular genetic diagnosis of LMX1B nephropathy
thus provides a definitive diagnosis, prevents the need for renal biopsies and allows at risk family
members to be screened.
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Introduction
Nail-patella syndrome (NPS, OMIM 161200) is a rare cause
of autosomal dominant end-stage renal disease (ESRD).
Typically, patients with NPS will exhibit extra-renal mani-
festations including absent/hypoplastic finger/toe nails
and patellae, elbow dysplasia and iliac horns [1]. Renal
manifestations occur in 30–50% of patients, and typically
include haematuria and proteinuria and sometimes neph-
rotic syndrome. ESRD occurs in 5–10% of cases [2, 3].
Mutations in the LIM homeodomain transcription factor
(LMX1B) underlie the molecular basis of NPS [4]. Ante-
natally, LMX1B is important for dorsal–ventral patterning,
and is also expressed in the developing glomerulus, within
S-shaped bodies. Murine data suggest that, post-natally,
LMX1B is necessary for podocyte maintenance, and regu-
lates expression of CD2AP, NPHS2 [5], COL4A3 and COL4A4
[6]. It has been suggested that intra-familial variation in
renal failure seen in NPS may relate to heterozygous var-
iants (which may segregate independently) in LMX1B-
regulated genes [2].
Recently, LMX1Bmutations have been identified in renal
limited forms of NPS, termed nail-patella-like renal
disease (NPLRD). Previous reports include three families
with an autosomal dominant pattern of focal and seg-
mental glomerular sclerosis (FSGS) in whommissense mu-
tations (two with R246Q and one with R246P) in LMX1B
were identified [7]. Another report detailed an R246Q
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missense mutation in LMX1B, which was associated with
childhood-onset microscopic haematuria and subnephro-
tic proteinuria but lacked any extra-renal manifestations
[8]. Thus, LMX1B is a candidate gene for autosomal dom-
inant nephropathies, including familial cases of FSGS and
unexplained proteinuria.
We describe a large family where affected individuals
had ESRD, chronic kidney disease or haematuria and pro-
teinuria in an autosomal dominant pattern. Renal biopsies
were unhelpful and failed to show glomerular or basement
membrane defects consistent with an inherited glomeru-
lopathy, and therefore we pursued a possible underlying
genetic cause for a unifying diagnosis. Using a combin-
ation of traditional linkage studies and inheritance by
descent (IBD) approaches with whole exome sequencing
(WES) strategies, we identified a novel heterozygous muta-
tion in LMX1B (p.R249Q) which segregated with disease.
Materials and Methods
Clinical and genetic investigations
Clinical data and historical renal biopsies were reviewed
where available. Following informed consent, DNA was
obtained from all affected patients and their unaffected
relatives where available. This study was approved by the
Northern and Yorkshire Regional Ethics Committee.
Genomic DNAwas extracted from blood samples collected
in EDTA tubes using the QIAGEN Blood and Cell Culture
DNA kit according to the manufacturer’s instructions.
Genotyping and linkage studies
We carried out a genome-wide linkage search using Affy-
metrix GeneChip® Human Mapping 250K Sty Arrays accord-
ing to the manufacturer’s protocol (http://www.affymetrix.
com) in six affected members and two unaffected
members of the family. Genehunter software was used to
calculate a multipoint parametric logarithm of odds (LOD)
score, assuming an autosomal dominant mode of inherit-
ance. IBD across the genome was estimated using Com-
binatorial Conflicting Homozygosity (CCH) [9].
Whole exome sequencing
WES was performed in three affected individuals from the
family using genomic DNA by AROS Applied Biotechnology
AS, Denmark. The reads were processed and analysed
using a comprehensive bioinformatics workflow to identify
variants. The quality of the reads was first checked with
FastQC [10]. Poly-N tails were trimmed off from reads with
an in-house Perl script. The 13 bp on the 50 of all reads
was clipped off with Seqtk [11] to remove biased sequen-
cing reads caused by random hexamer priming [12]. Low-
quality bases (Q≤ 20) and standard Illumina (Illumina,
Inc., CA, USA) paired-end sequencing adaptors on 30 ends
of reads were trimmed off using Trim Galore [13], and only
those that were at least 20 bp in length after trimming
were kept. High-quality reads were then mapped to the
human reference genome hg19 with Burrows-Wheeler
Aligner [14]. The alignments were then refined with tools
of the GATK suite [15]. Variants for the samples were
called according to the GATK Best Practice recommenda-
tions [16, 17]. This included recalibration. Non-synonym-
ous exonic variants were subsequently filtered by the
minor-allele frequency (MAF); as reported in 1000
Genomes 2011 release, ESP5400 and [18]. Variants with a
MAF of above 0.05 were excluded. ANNOVAR [19] was used
for annotations and prediction of functional conse-
quences. In parallel, causal variants in this study were
identified through the use of QIAGEN’s Ingenuity® Variant
Analysis™ software (www.qiagen.com/ingenuity) from
QIAGEN Redwood City.
Sanger sequencing was used to confirm whether var-
iants segregated with disease phenotypes. All coding
regions of the LMX1B gene were amplified and sequenced
directly using Sanger sequencing (primer sequences avail-
able on request), and segregation analysis was performed
using DNA samples from affected and unaffected
members of the family.
Homology modelling LMX1B
HHPred and Modeller were used to model the homeodo-
main of LMX1B (NP_002307) against the crystal structure
of the NKX2.5 homeodomain bound to ANF-242-DNA (PDB
code 3RKQ) [20]. A similar modelling strategy has been
recently reported [7]. The homology model was visualized
using PyMOL (http://www.pymol.org/).
Results
We report a large four generation family from the North
East of England, in whom there was an autosomal domin-
ant pattern of ESRD of unknown cause. The index case
(II:3) shown in Figure 1A presented at the age of 15 years
with dipstix proteinuria during a routine assessment
(Table 1). Subsequently, she developed nephrotic-range
proteinuria and progressive renal impairment leading to
ESRD by the age of 28 years. A renal biopsy was performed
which failed to provide a specific diagnosis. Her sibling
(II:5) initially presented with proteinuria during her first
pregnancy (aged 16 years), which was persistent but non-
progressive. However, during her third pregnancy, aged 29,
she developed hypertension and nephrotic-range protein-
uria. A renal biopsy (performed at the age of 30 years) de-
monstrated mesangial proliferative glomerulonephritis
with moderate granular deposits of C3 in the mesangium.
Electron microscopy was unable to demonstrate glomeru-
lar basement membrane (GBM) changes due to poor tissue
preservation. ESRD was reached at the age of 40 years. Pro-
teinuria in another sibling (II:4) was identified at the age
of 53 years during her workup as a potential living-related
kidney donor for II:3. Her renal function was preserved
(serum creatinine 79 µmol/L and eGFR >90). Given this
identification of three siblings with proteinuria, a screen of
additional family members was performed. The clinical
data are presented in Table 1. Clinical examination of af-
fected family members did not reveal any extra-renal
manifestations that would suggest NPS. Two unaffected
family members remained well with no proteinuria. II:6
successfully donated a kidney to his sibling II:3 and
remains well with no evidence of proteinuria.
Initial genetic studies were performed using a genome-
wide linkage approach. Affymetrix GeneChip® Human
Mapping 250K arrays were used to genotype eight family
members, including six affected members (II:2, II:3, II:4,
II:5, II:7 and III:3) and two unaffected members (II:1 and
II:6). LOD scores were calculated using Genehunter. Puta-
tive disease loci were identified in Chromosome 1 (LOD
1.505) and Chromosome 9 (LOD 1.505; Figure 1B). In
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Fig. 1. (A) Pedigree demonstrating an autosomal dominant pattern of disease. Circles represent females, and squares represent males. Shaded, affected.
(B) Selected LOD plots from genome-wide linkage studies showing maximal LOD scores (1.505) on Chromosome 1 and 9 (arrowed). (C) IBD analysis using
a CCH algorithm identified 12 loci in which there are >500 consecutive SNPs consistent with IBD. (D) Sequence chromatograms showing c.746G>A, p.
R249Q heterozygous change in LMX1B. (E) Amino acid alignment confirming evolutionary conservation of the arginine residue (R) at position 249 across
different species (reference sequence NM_002316.3). The R249Q missense mutation is predicted to be ‘probably damaging’ with a score of 1.000
(sensitivity: 0.00 and specificity: 1.00) using PolyPhen-2.
Table 1. Clinical features of affected and unaffected family members
Family ID Age at presentation Renal phenotype ESRD Comments
I:2 Unknown Haematuria/nephrotic-range proteinuria.
Renal biopsy non-diagnostic
No Died aged 45 years of myocardial infarction
II:1 Unaffected
II:2 Age 27 years with
proteinuria
CKD stage 2 aged 60, biopsy non-
diagnostic
No
II:3 Age 15 years with
proteinuria
Progressive proteinuria and renal
impairment
Age 28 years Renal transplant X3 (graft loss secondary to
chronic allograft nephropathy X2 and
transplant pyelonephritis)
II:4 Age 53 years with
proteinuria
Minimal proteinuria, preserved renal
function
No
II:5 Age 16 years with
proteinuria
Progressive nephrotic-range proteinuria,
exacerbated by pregnancy.
Renal biopsy (aged 30 years) showed early
mesangial proliferative
glomerulonephritis
Age 40 years Renal transplant X2 (graft loss secondary to
acute cellular rejection and chronic allograft
nephropathy)
II:6 Unaffected Living-related kidney donor to II:3
II:7 Age 23 years with
proteinuria
Progressive nephrotic-range proteinuria
and renal impairment.
Renal biopsy inconclusive
Age 44 years
III:3 Age 36 years with
proteinuria
CKD stage 2 aged 41 years.
Subnephrotic proteinuria
No
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parallel, IBD analysis was performed using a CCH algo-
rithm. This identified 12 loci in which there were >500 con-
secutive SNPs consistent with IBD, including the putative
loci on Chromosome 1 and Chromosome 9 (Figure 1C).
The Chromosome 1 region (Chr1: 184,113,318-184,118,
523) was gene poor and contained no candidate genes,
whereas the Chromosome 9 region (Chr9: 125,077,344-
131,145,855) was 6 Mb in length and included the candi-
date gene LMX1B.
Concurrent with traditional genetic approaches, WES
analysis was performed in three affected family members
(II:3, II:5 and II:7). Variant analysis identified 908 poten-
tially pathogenic variants. Variants were filtered for asso-
ciated kidney disease/expression within kidney tissue.
Potential disease variants were found in four candidate
genes, namely CDH6 (on Chromosome 5), MYH9 (on
Chromosome 22), LMX1B (on Chromosome 9) and CD9 (on
Chromosome 12). The variant in LMX1B was the only
variant that was compatible with an IBD hypothesis
within the identified putative disease loci. Sanger sequen-
cing of these genes was undertaken in all affected and
three unaffected family members. As expected from
linkage and IBD studies, the only variant which segre-
gated completely with disease was the c.746G>A; p.
R249Q LMX1B variant. Importantly, the LMX1B variant had
been identified using WES in all three of the patients
analysed, and Sanger sequencing confirmed its presence
in all affected family members (Figure 1D). There were no
additional variant alleles identified following sequencing
of the whole coding region of LMX1B. The variant was
absent from unaffected family members. The mutation
c.746G>A; p.R249Q (Reference sequence NM_002316.3) is
novel and is not present in databases including 1000
Genomes (http://www.1000genomes.org/), Exome Variant
Server (http://evs.gs.washington.edu/EVS/) or the Exome
Aggregation Consortium” (ExAC) data set with exome se-
quence data obtained from 63 352 individuals (http://exac.
broadinstitute.org/). There are, however, two previous
reports of pathogenic missense mutations at the identical
amino acid position occurring in NPS patients, namely
c.745C>G; p.R249G [reported as c.676C>G; p.R226G, using
a shorter isoform of LMX1B (NM_001174147.1) as refer-
ence [21]] and c.746G>C; p.R249P [reported as c.677G>C;
p.R226P again using the shorter isoform of LMX1B (NM_
001174147.1) as reference [22]].
The arginine residue at position 249 in LMX1B is highly
conserved in the DNA-binding motif of homeodomain-
containing proteins [23] and across various species
(Figure 1E). The LMX1B protein consists of two amino-ter-
minal zinc-binding LIM domains and a homeodomain,
which functions to regulate target gene transcription
(Figure 2A). In silico modelling of LMX1B revealed that
R249 is putatively located in close proximity to the back-
bone of the DNA strand (Figure 2B), where the positively
charged side-chain is well placed to interact with the
negatively charged DNA phosphoskeleton. Mutation of
R249 to proline (reported as R226P [22]) was shown to
impair DNA binding in vitro using an electrophoretic mobil-
ity shift assay and reduced transactivation by >90% in an
in vitro luciferase reporter assay [24]. The novel R249Q
mutation we have identified is also predicted to affect the
homeodomain–DNA interaction (PolyPhen-2 score, 1.000).
Fig. 2. (A) Schematic representation of the predicted domain structure of LMX1B including LIM domains and a DNA-binding homeodomain. The position
of the R249Q mutation in helix II of the homeodomain is indicated. (B) The homeodomain of LMX1B (shown in green) was modelled against the crystal
structure of the NKX2.5 homeodomain (shown in orange; PDB code 3RKQ). The NKX2.5 homeodomain structure was determined in complex with DNA
(shown in grey) from the proximal promoter region of the atrial natriuretic factor (ANF) gene [20]. The position of the LMX1B residues mutated in NPS,
R246 and R249 (homologous to R31 in NKX2.5) are highlighted. Modelling of wild-type (C) and R249Q mutant (D) LMX1B homeodomain. The shorter and
uncharged side-chain of glutamine in the R249Q mutant is predicted to disrupt DNA binding.
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Analysis of variants in transcriptional target genes was
undertaken in the three affected family members who
had undergone WES using QIAGEN’s Ingenuity® Variant
Analysis™ software. In this analysis, no additional patho-
genic variants associated with proteinuria or podocytopa-
thies were detected.
Discussion
This case and others recently described make it clear that
mutations in LMX1B may lead to renal-limited disease,
and we support the suggested terminology of LMX1B ne-
phropathy [8]. Although important in developmental pro-
cesses, including limb formation, it is now clear that
LXM1B is also important for post-natal podocyte function.
Where there are no extra-renal features of classical NPS, a
renal biopsy is often performed, given the renal-limited
phenotype of proteinuria and cystic kidney disease (CKD)/
ESRD of unknown cause. In NPS, renal histological features
may be subtle. Light microscopy may not reveal any glom-
erular abnormalities, and direct immunofluorescence is
usually negative. Electron microscopy may reveal podo-
cyte foot process effacement and irregular thickening of
the GBM [25, 26]. Often the GBM is noted to have a moth-
eaten appearance [8].
Recently, LMX1Bmutations have been associated with a
histological picture of FSGS, without extra-renal features
[7]. Boyer et al. [7] describe a large family, where two
index cases presented with nephrotic-range proteinuria
and FSGS on renal biopsy. Electron microscopy performed
on one of the biopsy samples, even after reprocessing and
reanalysis, failed to show GBM changes typical of NPS.
LMX1B mutations were also identified in two additional
families who had an autosomal dominant pattern of
nephrotic syndrome, whose histology was consistent with
FSGS and minimal change disease, respectively [7]. Inter-
estingly, detailed immunohistological analysis of a renal
biopsy of a 6-year-old child with LMX1B nephropathy
(where light microscopy showed normal glomeruli and no
abnormalities of the GBM) revealed a cytoplasmic granular
staining pattern for CD2AP, rather than a linear staining
pattern seen in control samples [8]. In light of these
reports, LMX1B, therefore, becomes a candidate gene for
non-syndromic autosomal dominant FSGS [27] and auto-
somal-dominant forms of minimal change disease.
The pathogenesis of the renal phenotype has been in-
vestigated in murine studies. Lmx1b is expressed in
murine glomeruli [28]. In Lmx1b-null mice, podocyte foot
processes are reduced in number and are dysplastic [5]. In
vitro, LMX1B binds to and regulates the transcription of
CD2AP and NPHS2 [5], thus regulating key podocyte genes
critical for podocyte function. Reduced Col4a3 and Col4a4
transcript expression has also been noted in Lmx1b-null
mice, leading to reduced expression of their encoded type
IV collagen proteins [6].
It has been suggested that variants in genes under the
transcriptional control of LMX1B may account for the
intra-familial variability of renal dysfunction seen in NPS
[2]. In the family we report here, there were extremes of
phenotypes, with proteinuria presenting in teenage years
leading to ESRD before 30 years of age contrasting with
minimal proteinuria and preserved renal function at the
age of 53 years. Given that three affected members had
undergone WES, we were able to examine for pathogenic
variants in genes associated with podocytopathies, but
we found no predicted disease-causing variants within
these genes, including CD2AP, NHPS2, COL4A3, COL4A4
and COL4A5.
There are no specific treatments for LMX1B nephropathy.
Treatment of proteinuria and hypertension with ACE inhibi-
tors/angiotensin receptor blockers is recommended, but it
is not known whether prophylactic treatment with these
agents is helpful to prevent disease progression. Successful
treatment of significant proteinuria in a 6-year-old child
with NPS was achieved with combination of enalapril and
losartan therapy [29], and that observation certainly
argues the case for titration of drugs to achieve effective
blocking of the renin–angiotensin–aldosterone system.
As seen in the family presented, proteinuria and renal
impairment may be exacerbated during pregnancy. The
clinical course is unpredictable, again as demonstrated
here, with some patients progressing rapidly to ESRD and
others having many years of asymptomatic proteinuria.
ESRD occurs in 5–10% of NPS patients [2, 3] at a mean
age of 33 years [30]. Renal transplantation is usually
successful in this condition, with no disease recurrence in
the renal allograft, and these patients do not develop
anti-GBM antibodies.
Missense mutations within the homeodomain are likely
to disrupt DNA binding [24, 31], and there is evidence that
patients with mutations located in the homeodomain
have more proteinuria than those with LIM domain muta-
tions [32]. Homology modelling of LMX1B using the crystal
structure of the NKX2.5 homeodomain [20] supports a
role for R249 in DNA interaction for subsequent transcrip-
tional activity (Figure 2B). The Nε atom of the homologous
arginine residue in NKX2.5 (R31) forms a salt bridge with a
phosphate group of the DNA backbone to provide anchor
for the DNA recognition helix [23]. The R249Q mutation
reported here is predicted to impair the LMX1B–DNA inter-
action, likely through loss of the positively charged side-
chain. Mutation of R249 to proline (reported as R226P)
reduced DNA binding by the LMX1B homeodomain in vitro
[22]. A similar effect would also be anticipated for the
NPS-linked R249G mutation (reported as R226G) [22]. The
functional importance of this region of the LMX1B homeo-
domain is further highlighted by homology modelling of
the R246 residue (Figure 2B). Several NPS-linked mutations
of R246 have been reported [7, 8], and LMX1B–R246Q
exhibited partially impaired transcriptional activity in vitro
[8].
Increasingly in patients in whom we suspect an inher-
ited renal disease, genetic investigations may be more de-
finitive and diagnostic than renal biopsies [33].
Historically, a genetic diagnosis in kidney disease has
been limited to patients and families, where clinical or
histological data display distinctive features that suggest
one or a small number of candidate genes that can be se-
quenced individually. However, with the advent of mas-
sively parallel (next-generation) sequencing, a large
number of genes can now be investigated in a single
patient at a cost that can reasonably be borne by health-
care providers. The benefit of this approach is that it can
allow a precise molecular diagnosis to be made even in
patients where clinical data are lacking or non-specific,
and can sometimes obviate the need for invasive tests
such as a kidney biopsy.
However, because a large number of genes are tested
simultaneously, the prior probability that any one of the
genes or variants identified is responsible for disease is
low. While variants known to be common in the healthy
population can usually be excluded from consideration, it
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is not always possible to determine whether a rare or
novel variant identified in a patient is actually pathogenic.
This is because, even where they change the amino acid
sequence of a protein, not all genetic variants change
protein function or cause disease. Typically several lines of
evidence (including linkage data, co-segregation analysis,
comparison with mutation databases and functional and
structural data about the protein) are needed to make a
diagnosis securely. Over time, as sequence databases, in-
corporating data from larger numbers of patients and
healthy individuals, become available to clinicians, the
power of this approach is likely to increase.
We suggest that in all cases of ESRD of uncertain/
unknown cause, a family history is sought. If an autosomal
dominant pattern of CKD/ESRD is identified, then an
underlying genetic disorder should be considered. There
are a growing number of genetic causes of autosomal
dominantly inherited renal failure, such that a candidate
gene approach would be too costly and time consuming.
We anticipate, however, that next-generation sequencing
(NGS) approaches, and even whole genome sequencing
approaches (WGS), will in the future allow a fast, cost ef-
fective and definitive genetic diagnosis to be made.
Clearly, the advantages of an early diagnosis of an inher-
ited renal disease allow therapies to be instituted, directed
towards reducing blood pressure and proteinuria and
perhaps the disease itself. Plans regarding ESRD, trans-
plantation and risk of recurrent disease can be more easily
discussed and relatives at risk of the disease can be
screened, thereby avoiding invasive renal biopsies and
multiple other investigations.
In conclusion, using genetic investigations in a large
family affected by proteinuria, CKD and ESRD in whom
renal biopsies had been uninformative, we have identified
a novel mutation in LMX1B. The mutation segregated with
the disease phenotype of LMX1B nephropathy. Genetic in-
vestigations of families with similar phenotypes should be
a priority for nephrologists, and the advent of NGS and
WGS will make this both practical and cost effective.
Acknowledgements. We sincerely thank patients and family
members for their support. This work was supported by the Nor-
thern Counties Kidney Research Fund. S.J.R. is supported by a MRC
PhD studentship.
Conflict of interest statement. The results presented in this paper
have not been published previously in whole or part.
References
1. Turner JW. A hereditary arthrodysplasia associated with her-
editary dystrophy of the nails. J Am Med Assoc 1933; 100: 882
2. Lemley KV. Kidney disease in nail-patella syndrome. Pediatr
Nephrol 2009; 24: 2345–2854
3. Sweeney E, Fryer A, Mountford R et al. Nail patella syndrome:
a review of the phenotype aided by developmental biology. J
Med Genet 2003; 40: 153–162
4. Dreyer SD, Zhou G, Baldini A et al. Mutations in LMX1B cause
abnormal skeletal patterning and renal dysplasia in nail
patella syndrome. Nat Genet 1998; 19: 47–50
5. Miner JH, Morello R, Andrews KL et al. Transcriptional induc-
tion of slit diaphragm genes by Lmx1b is required in podocyte
differentiation. J Clin Invest 2002; 109: 1065–1072
6. Morello R, Zhou G, Dreyer SD et al. Regulation of glomerular
basement membrane collagen expression by LMX1B
contributes to renal disease in nail patella syndrome. Nat
Genet 2001; 27: 205–208
7. Boyer O, Woerner S, Yang F et al. LMX1B mutations cause
hereditary FSGS without extra-renal involvement. J Am Soc
Nephrol 2013; 24: 1216–1222
8. Isojima T, Harita Y, Furuyama M et al. LMX1B mutation with
residual transcriptional activity as a cause of isolated glomer-
ulopathy. Nephrol Dial Transplant 2014; 29: 81–88
9. Levine AP, Connor TM, Oygar DD et al. Combinatorial Conflict-
ing Homozygosity (CCH) analysis enables the rapid identifica-
tion of shared genomic regions in the presence of multiple
phenocopies. BMC Genomics 2014 (in press).
10. Andrews S. FastQC A Quality Control tool for High Throughput
Sequence Data. http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/
11. Li H. Seqtk. https://github.com/lh3/seqtk
12. Hansen KD, Brenner SE, Dudoit S. Biases in Illumina transcrip-
tome sequencing caused by random hexamer priming.
Nucleic Acids Res 2010; 38: e131
13. Krueger F. Trim Galore! http://www.bioinformatics.babraham.
ac.uk/projects/trim_galore/
14. Li H, Durbin R. Fast and accurate long-read alignment with
Burrows–Wheeler transform. Bioinformatics 2010; 26:
589–595
15. McKenna A, Hanna M, Banks E et al. The Genome Analysis
Toolkit: a MapReduce framework for analyzing next-generation
DNA sequencing data. Genome Res 2010; 20: 1297–1303
16. DePristo MA, Banks E, Poplin R et al. A framework for variation
discovery and genotyping using next-generation DNA se-
quencing data. Nat Genet 2011; 43: 491–498
17. Van der Auwera GA, Carneiro MO, Hartl C et al. From FastQ
Data to High-Confidence Variant Calls: The Genome Analysis
Toolkit Best Practices Pipeline. Current Protocols in Bioinfor-
matics. Hoboken, USA: JohnWiley & Sons, Inc., 2002
18. Blazer S, Zimmer EZ, Blumenfeld Z et al. Natural history of
fetal simple renal cysts detected in early pregnancy. J Urol
1999; 162(3 Pt 1): 812–814
19. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation
of genetic variants from high-throughput sequencing data.
Nucleic Acids Res 2010; 38: e164
20. Pradhan L, Genis C, Scone P et al. Crystal structure of the
human NKX2.5 homeodomain in complex with DNA target.
Biochemistry 2012; 51: 6312–6319
21. Dunston JA, Hamlington JD, Zaveri J et al. The human LMX1B
gene: transcription unit, promoter, and pathogenic muta-
tions. Genomics 2004; 84: 565–576
22. McIntosh I, Dreyer SD, Clough MV et al. Mutation analysis of
LMX1B gene in nail-patella syndrome patients. Am J Hum
Genet 1998; 63: 1651–1658
23. Chi YI. Homeodomain revisited: a lesson from disease-
causing mutations. Hum Genet 2005; 116: 433–444
24. Dreyer SD, Morello R, German MS et al. LMX1B transactivation
and expression in nail-patella syndrome. Hum Mol Genet
2000; 9: 1067–1074
25. Del Pozo E, Lapp H. Ultrastructure of the kidney in the nephro-
pathy of the nail—patella syndrome. Am J Clin Pathol 1970;
54: 845–851
26. Ben-Bassat M, Cohen L, Rosenfeld J. The glomerular base-
ment membrane in the nail-patella syndrome. Arch Pathol
1971; 92: 350–355
27. Kopp JB. An expanding universe of FSGS genes and pheno-
types: LMX1B mutations cause familial autosomal dominant
FSGS lacking extra-renal manifestations. J Am Soc Nephrol
2013; 24: 1183–1185
28. Suleiman H, Heudobler D, Raschta AS et al. The podocyte-
specific inactivation of Lmx1b, Ldb1 and E2a yields new
insight into a transcriptional network in podocytes. Dev Biol
2007; 304: 701–712
29. Proesmans W, Van Dyck M, Devriendt K. Nail-patella syn-
drome, infantile nephrotic syndrome: complete remission
118 N. Edwards et al.
with antiproteinuric treatment. Nephrol Dial Transplant 2009;
24: 1335–1338
30. Looij BJ Jr, te Slaa RL, Hogewind BL et al. Genetic counselling
in hereditary osteo-onychodysplasia (HOOD, nail-patella
syndrome) with nephropathy. J Med Genet 1988; 25:
682–686
31. Bongers EM, Gubler MC, Knoers NV. Nail-patella syndrome.
Overview on clinical and molecular findings. Pediatr Nephrol
2002; 17: 703–712
32. Bongers EM, Huysmans FT, Levtchenko E et al. Genotype-
phenotype studies in nail-patella syndrome show that LMX1B
mutation location is involved in the risk of developing nephro-
pathy. Eur J Hum Genet 2005; 13: 935–946
33. Adam J, Connor TM, Wood K et al. Genetic testing can resolve
diagnostic confusion in Alport syndrome. Clin Kidney J 2014;
7: 197–200
Received for publication: 7.10.14; Accepted in revised form: 5.11.14
Novel LMX1B mutation 119
